Bacteremia or endocarditis caused by MRSA or methicillin-resistant coagulase-negative staphylococci in a patient with a serious allergy to vancomycin (NOT Vancomycin Flushing Syndrome)
Therapy for MRSA infections (other than pneumonia) in which the MIC of vancomycin is ≥2 mcg/mL
Bacteremia or endocarditis caused by MRSA in a patient failing vancomycin therapy defined as:
Therapy for VRE infections other than pneumonia
Targeted therapy of resistant gram positive infections with MRSA (particularly when MIC>=2) and VRE including endovascular infection
Laboratory
Clinical
Statins and Fibrates: Monitor creatine kinase while on daptomycin therapy (increased myopathy)
Inactivated by pulmonary surfactant and therefore insufficient for pulmonary infection.
Antimicrobial class: Cyclic lipopeptide. Depolarizes bacterial cell membrane.
Pregnancy category: B
Average serum half life: 9 hours
CSF penetration: Poor
Urine penetration: Therapeutic